Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
CA 2518924 C · Owner: Fino, Mireli · Inventors: Alonso-Caplen, Firelli; Pursell, Earl Joseph; Cutler, Mark William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A process for producing isolated and purified respiratory syncytial virus (RSV) fusion (F) and attachment (G) glycoproteins in eukaryotic cell cultures infected with RSV cold-passaged, temperature-sensitive mutant subgroup A2 strain cpts-248/404 results in at least a 5-fold increase in F and G protein yields when compared with the parent A2 strain. Immunogenic compositions comprising the F and/or G protein(s) produced by this process can be formulated for in vivo administration to a host to confer protection against disease caused by RSV.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 2004 and granted June 7, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 17, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.